Viyash Scientific Limited · NSE:VIYASH
Viyash Scientific — SeQuent Scientific — Q3 FY2020 Earnings Presentation
31 slides from Viyash Scientific's earnings presentation, Jan 28, 2020
Slide 1: Outcome of Board Meeting letter to exchanges
Proven Ability In Life Sciences January 28, 2020 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai-400 001. Mumbai-400 051. Scrip code: 5
Slide 2: Independent Auditor's Review Report - Consolidated
SR BC & CO LLP 12th Floor, The Ruby 29 Senapati Bapat Marg Chartered Accountants Dadar (West) Mumbai - 400 028, India Tel : +912268198000 Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the
Slide 3: Auditor's Review Report (continued)
SR BC& CO LLP Chartered Accountants 6. The accompanying Statement includes unaudited interim financial results and other unaudited financial information of twelve subsidiaries, whose interim financial results reflect Group's share of total revenues of Rs. 19,357 lakhs and Rs. 50,857 lakhs, Group's s
Slide 4: Annexure I to Auditor's Report
SR BC& CO LLP Chartered Accountants Annexure I to Auditor's Report Name of the Entity 1. SeQuent Research Limited Wholly Owned Subsidiary 2. Elysian Life Sciences Private Limited Wholly Owned Subsidiary 3. SeQuent Pharmaceuticals Private Limited (Upto July 26, 2019) Wholly Owned Subsidiary 4. SeQuen
Slide 5: Statement of Unaudited Consolidated Financial Results
SeQuent Pi·oven Ability In Life Sciences SEQUENT SCIENTIFIC LIMITED STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2019 ('l in Lakhs) Yearta d at e Corresponding 3 Yea r to date figure 3 months Prece ding 3 figure for the Prev ious yea r month
Slide 6: Notes to Consolidated Results
SeQue nt Pruvi;,:n AbilihJ In l.jfe f'><::ien,·:.e s SEQUENT SCIENTIFIC LIMITED Notes: 1. The above unaudited consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors al its meeting held on 28 January 2020. The statutory auditors have carried li
Slide 7: Independent Auditor's Review Report - Standalone
SR BC& CO LLP 12th Floor, The Ruby 29 Senapati Bapat Marg Chartered Accountants Dadar (West) Mumbai - 400 028, India Tel :+912268198000 Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEB
Slide 8: Statement of Unaudited Standalone Financial Results
SeQuent f'('('.>V<'.~n Ability ln Lifo~ ~x:lerK.es. SEQUENT SCIENTIFIC LIMITED STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31 DECEMBER 2019 (if in Lakhs) 3 months Preceding Corresponding Year to date Year to date Previous year ended 3 months 3 months end
Slide 9: Notes to Standalone Results
SeQuent Pr-0ven Ability In Ufe Scien<.'L"S SEQUENT SCIENTIFIC LIMITED Notes: 1 The above unaudited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 28 January 2020. The statutory auditors have carried limited review
Slide 10: SeQuent Scientific Announces Q3 FY20 Financial Results
SeQuent Scientific Announces Q3 FY20 Financial Results Q3 FY20 - EBITDA up 36% with 56% growth in PAT 9M FY20 - EBITDA up 35% with 68% growth in PAT Mumbai, January 28, 2020 SeQuent Scientific Limited (SeQuent), which has businesses across Animal Health (Alivira) & Analytical Services today announce
Slide 11: For details, feel free to contact
For details, feel free to contact: Tushar Mistry Chief Financial Officer Tel: +91 22 4111 4717 Registered Office tushar.m@sequent.in 301/A, ‘Dosti Pinnacle', Plot No. E7, Road No. 22, Wagle Industrial Area, Thane (W), Maharashtra, India CIN: L99999MH1985PLC036685 Diwakar Pingle BSE Code:512529 I NSE
Slide 12: Earnings Presentation Q3 & 9M FY20
Earnings Presentation Q3 & 9M FY20 January 28, 2020
Slide 13: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as "will", "aim", "will likely result", "would", "believe", "may", "expect", "will continue", "anticipate", "estimate", "intend", "pl
Slide 14: Q3 & 9M FY20 Performance Review
SeQuent Proven Abi .ife Sciences ALIVIRA Q3 & 9M FY20 Performance Review
Slide 15: Strong quarter backed by operational excellence
Strong quarter backed by operational excellence Revenues EBITDA margin PAT Cash from operations ₹3,164 15.3% ₹203 ₹465 Million Million Million 17.0% 220bps 55.9% 2.4x YoY YoY YoY QoQ 4
Slide 16: Industry leading growth
Industry leading growth All values in ₹ Mn Q3 FY2020 YOY 9M FY2020 YOY Q3 FY20 3,164 9M FY20 8,787 Revenues 17.0% 16.0% Q3 FY19 2,705 9M FY19 7,574 Q3 FY20 484 9M FY20 1,247 EBITDA 36.4% 34.9% Q3 FY19 355 9M FY19 924 Q3 FY20 203 9M FY20 531 PAT Q3 FY19 130 55.9% 9M FY19 315 68.2% “We are pleased wit
Slide 17: Strong performance across businesses
Strong performance across businesses All values in ₹ Mn Revenue YoY% YoY% Q3 FY20 Q3 FY19 YoY% 9M FY20 9M FY19 YoY% Distribution (Constant currency) (Constant currency) Formulations 2,113 1,812 16.6% 22.4% 5,856 5,338 9.7% 14.9% Europe 974 946 3.0% 7.4% 2,700 2,774 (2.7%) 0.8% Turkey 379 162 134.3%
Slide 18: Q3 & 9M FY20 Business Review
SeQuent Proven Abi .ife Sciences ALIVIRA Q3 & 9M FY20 Business Review
Slide 19: APIs
APIs Scaling the 26 18 11 14+ capability curve Commercial APIs US filings/ CEP filings Pipeline approvals Revenues in ₹ Mn Highlights YoY% 9M FY20 9M FY19 (cc) Focus on regulated markets/customers and high value products continues to drive up 2,931 2,236 30.1% fixed asset turn for the business, now
Slide 20: Alivira amongst 'Top 3' US FDA VMF Filers
Alivira amongst ‘Top 3’ US FDA VMF Filers US Veterinary Master File Strategic product selection Innovator Cos Integrated Cos API Cos API Filings Competition 42 40 5 Alivira only 7 < 3 competitors 17 17 12 5 5+ competitors 10 8 6 6 6 Player A Player B Player C Player D Alivira Player E Player F Playe
Slide 21: Formulations
Formulations Value creation 35+ 80+ 1,000+ 50+% Products Under Countries with FDFs Sales to regulated Development marketing presence markets Revenues in ₹ Mn Highlights YoY% 9M FY20 9M FY19 (cc) Regulatory headwinds completely behind in Turkey; revenue grew 86.7% in 9M 5,856 5,338 14.9% EU reported
Slide 22: Scaling value curve
Scaling value curve US filed / EU-CEP Pipeline approved approvals 2 US filings during the financial year API 14+ 18 10 New R&D facility established in Mumbai to build regulated market pipeline US only Globally EU only 10 new filings in US in next 3 years 3 Products 8 Products 18 Products Formulation
Slide 23: R&D facility established in Mumbai
R&D facility established in Mumbai State of the Art Global infrastructure and Multifaceted Capability • Footprint - 3,200 sq. ft • Multi Dosage Capability – 8 • Specialized in Injectables & Tablets • Robust scalability - Lab to Pilot Team • Multidisciplinary Team of 20 scientists 100+ years of cumul
Slide 24: Financials
SeQ.uent Proven Ability In Life Sciences ALIVIRA Financials
Slide 25: Relentless Execution
Relentless Execution All values in ₹ Mn Revenue Revenue 3,164 2,780 2,842 2,819 2,517 2,705 2,352 2,249 2,328 1,942 1,975 8,787 7,574 6,167 4,887 Q1 Q2 Q3 Q4 9M17 9M18 9M19 9M20 EBITDA EBITDA 15.3% 13.9% 13.3% 14.3% 13.1% 12.7% 13.2% 10.6% 10.0% 1,247 7.6% 9.6% 484 402 924 385 320 378 355 250 226 30
Slide 26: Consolidated Financials
Consolidated Financials All values in ₹ Mn Q3 FY20 Q2 FY20 Q3 FY19 9M FY20 9M FY19 FY19 PARTICULARS Unaudited H1 FY20 Unaudited Unaudited Unaudited Unaudited Audited Revenue from Operations 3,164 2,842 2,705 8,787 5622 7,574 10,393 Material Consumption (1,617) (1,508) (1,412) (4,557) (2939) (3,988)
Slide 27: Key Balance Sheet items
Key Balance Sheet items All values in ₹ Mn ROCE** Net debt to EBITDA Particulars Dec-19 Sep-19 14.1% 3.75 11.8% 2.81 Shareholders' funds 7,342 6,878 7.8% 1.84 1.41 2.9% Minority Interest 428 401 FY17 FY18 FY19 FY20 9M* FY17 FY18 FY19 FY20 9M* Net Debt 2,340 2,736 *9M Annualised **Adjusted for invest
Slide 28: FY20 Outlook
SeQ.uent Proven Ability In Life Sciences ALIVIRA FY20 Outlook
Slide 29: Creating value for all stake-holders
Creating value for all stake-holders Remain confident on achieving FY20 outlook FY20 Outlook 9M FY20 status ▪ High-teen ▪ 16.0% revenue revenue growth growth ▪ 200+ bps margin ▪ 200 bps margin expansion expansion 18
Slide 30: Thank You
Thank You SeQuent Scientific Limited CIN: L99999MH1985PLC036685, Registered Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22,Wagle Industrial Estate, Thane (W) - 400 604, Maharashtra Tel No: 491 22 4111 4777 | Website: www.sequent.in | E-mail id: info@sequent.in
Slide 31: For details, feel free to contact
For details, feel free to contact: Tushar Mistry Diwakar Pingle Abhishek Singhal Chief Financial Officer Christensen Investor Relations Investor Relations Consultant +91 22 4111 4717 +91 22 4215 0210 abhishek.s@sequent.in tushar.m@sequent.in dpingle@christensenir.com Registered Office: 301/A, ‘Dosti